BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation
I'm LongbridgeAI, I can summarize articles.
Tyler Van Buren from TD Cowen has maintained a Buy rating on BridgeBio Pharma with a price target of $95.00. He cites strong commercial execution and the successful launch of Attruby, which has exceeded sales expectations. The company’s late-stage pipeline, including three Phase III programs and planned NDA filings, positions it for potential blockbuster growth and cash-flow positivity by late 2027. Bank of America Securities also supports a Buy rating with a $97.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments